Nxstage Medical, Inc. (NXTM) Discloses Insider Transaction. Joseph E Jr Turk , President of Nxstage Medical, Inc. sold 2,839 shares on Jun 10, 2015. The Insider selling transaction was disclosed on Jun 10, 2015 to the Securities and Exchange Commission. The shares were sold at $16.00 per share for a total value of $45,424.00.

In a SEC Form 4 Filing, Company has also disclosed other Insider Transactions , According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the (President) of Nxstage Medical, Inc., Turk Joseph E Jr had sold 2,000 shares worth of $33,280 in a transaction dated May 26, 2015. In this transaction, 2,000 shares were sold at $16.64 per share. 12.08% of the shares are held by the company Insiders, 91.2% of the shares are held by the institutions. Company shares has an average 3 month share volume of 481,040 and an average 10 day volume is recorded to be 320,114

NxStage Medical, Inc. (NASDAQ:NXTM) witnessed a volatile trading activity on Tuesday and eventually ended flat at 0% or 0 points without letting the bulls or bears take much advantage. The trading began at $16.09 and reached the intraday high at $16.13. The bulls started the profit booking and pushed the shares to intraday low of $15.85. The trading session was marked by a volume range of 817,428 shares exchanging hands. The 52-week high of the shares is $19.63 and the 52-week low is $11.5. The market cap of the company stands at $1,013 million and there are 63,238,000 shares in public circulation. The company has received recommendation from many analysts. 5 analysts have rated the company as a strong buy. The shares has been rated as hold from 1 Wall Street Analysts. 1 analysts have suggested buy for the company.1 analyst has also rated it as a strong sell.

NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.

...